Neumora Therapeutics, Inc. financial data

Symbol
NMRA on Nasdaq
Location
Watertown, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 06 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 920% % -42%
Debt-to-equity 17% % 158%
Return On Equity -114% % -55%
Return On Assets -97% % -41%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 167,089,114 shares 3.4%
Common Stock, Shares, Outstanding 161,710,000 shares 1.8%
Entity Public Float $823,800,000 USD
Common Stock, Value, Issued $16,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 161,838,000 shares 1.4%
Weighted Average Number of Shares Outstanding, Diluted 161,838,000 shares 1.4%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $177,307,000 USD -8.5%
General and Administrative Expense $63,291,000 USD 12%
Operating Income (Loss) $245,598,000 USD 22%
Nonoperating Income (Expense) $9,431,000 USD -56%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $236,167,000 USD 22%
Income Tax Expense (Benefit) $0 USD -100%
Net Income (Loss) Attributable to Parent $236,297,000 USD 20%
Earnings Per Share, Basic -1 USD/shares -28%
Earnings Per Share, Diluted -1 USD/shares -28%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $129,071,000 USD -53%
Marketable Securities, Current $42,454,000 USD -35%
Assets, Current $177,082,000 USD -49%
Property, Plant and Equipment, Net $80,000 USD -94%
Operating Lease, Right-of-Use Asset $474,000 USD -82%
Other Assets, Noncurrent $197,000 USD
Assets $177,833,000 USD -50%
Accounts Payable, Current $549,000 USD -91%
Employee-related Liabilities, Current $8,858,000 USD 0.16%
Accrued Liabilities, Current $24,982,000 USD 9.8%
Liabilities, Current $25,842,000 USD -19%
Operating Lease, Liability, Noncurrent $267,000 USD
Liabilities $45,672,000 USD 44%
Accumulated Other Comprehensive Income (Loss), Net of Tax $9,000 USD -91%
Retained Earnings (Accumulated Deficit) $1,124,699,000 USD -27%
Stockholders' Equity Attributable to Parent $132,161,000 USD -59%
Liabilities and Equity $177,833,000 USD -50%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $59,448,000 USD -38%
Net Cash Provided by (Used in) Financing Activities $0 USD -100%
Net Cash Provided by (Used in) Investing Activities $44,160,000 USD
Common Stock, Shares Authorized 700,000,000 shares 0%
Common Stock, Shares, Issued 161,710,000 shares 1.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $15,288,000 USD 92%
Interest Paid, Excluding Capitalized Interest, Operating Activities $747,000 USD
Deferred Tax Assets, Valuation Allowance $264,379,000 USD 34%
Deferred Tax Assets, Gross $264,917,000 USD 33%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $236,393,000 USD 19%
Lessee, Operating Lease, Liability, to be Paid $1,892,000 USD -66%
Property, Plant and Equipment, Gross $3,189,000 USD -1.1%
Operating Lease, Liability, Current $256,000 USD -91%
Lessee, Operating Lease, Liability, to be Paid, Year One $1,892,000 USD -49%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $39,000 USD -90%
Deferred Tax Assets, Operating Loss Carryforwards $112,075,000 USD 42%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 50,000,000 shares
Unrecognized Tax Benefits $9,681,000 USD 12%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $157,000 USD -0.63%
Deferred Tax Assets, Net of Valuation Allowance $538,000 USD -64%
Share-based Payment Arrangement, Expense $32,372,000 USD -10%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%